Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) saw a significant increase in short interest in August. As of August 15th, there was short interest totalling 165,800 shares, an increase of 523.3% from the July 31st total of 26,600 shares. Currently, 3.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,510,000 shares, the short-interest ratio is currently 0.1 days.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned approximately 1.95% of Bluejay Diagnostics at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.47% of the company’s stock.
Bluejay Diagnostics Stock Performance
Shares of NASDAQ BJDX traded up $0.01 during midday trading on Tuesday, reaching $0.22. The company’s stock had a trading volume of 4,100,695 shares, compared to its average volume of 643,948. Bluejay Diagnostics has a fifty-two week low of $0.20 and a fifty-two week high of $53.28. The business’s 50 day moving average price is $0.83 and its two-hundred day moving average price is $3.70. The company has a market cap of $73,684.80, a P/E ratio of 0.00 and a beta of 0.81.
Bluejay Diagnostics Company Profile
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Articles
- Five stocks we like better than Bluejay Diagnostics
- How to Evaluate a Stock Before Buying
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- What is a Secondary Public Offering? What Investors Need to Know
- Brinker International Offers a Pullback Opportunity on EPS Miss
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
